Roche Diabetes Care distributes the Eversese® CGM system in Europe

Roche Diabetes Care distributes the Eversese® CGM system in Europe, the Middle East and Africa.

Senseonics Holdings, Inc., is a medical technology company focused on the development and marketing of a continuous glucose monitoring system (CGM) in the long -term implantable to announce today that it has expanded its exclusive distribution agreement with Roche to include allEurope, the Middle East and Africa (EMEA), excluding Scandinavia, Finland and Israel.

In May of this year, Senseonics signed an exclusive distribution with Roche for the marketing of the Senseonics Evennesonics continuous glucose monitoring system in Germany, Italy and the Netherlands.

More information at: Link

The problem I see is apart from how invasive it is, could ignore it, having to carry the transmitter attached to the body, I do not understand why the sensor itself has not been trained of a micro transmitter by Bluetooth or NFC, (theBluetooth transmission is not very safe), with a good management app.It will be necessary to see what the results give and above all the user experience to perform almost a small surgical intervention for extraction.

This video shows the Eversese system, Roche's MCG system.He says last 180 days.You have to look at the prices (it is in UK), but it in particular seems to me based expensive.And it must be added that the sensor is lodged under the skin, which entails a small surgery.
Link

There is an equal open thread about the Eversese.Please continue in the other thread to avoid duplicities of comments and that people are easier to locate all the information of that product in the same thread.
Thank you.

Link